These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 11457751)

  • 1. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
    Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Senthil V; Chen SN; Tsybouleva N; Halder T; Nagueh SF; Willerson JT; Roberts R; Marian AJ
    Circ Res; 2005 Aug; 97(3):285-92. PubMed ID: 16020756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.
    Nagueh SF; Chen S; Patel R; Tsybouleva N; Lutucuta S; Kopelen HA; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
    J Mol Cell Cardiol; 2004 May; 36(5):663-73. PubMed ID: 15135661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Nagueh SF; Kopelen HA; Lim DS; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
    Circulation; 2000 Sep; 102(12):1346-50. PubMed ID: 10993850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.
    Lombardi R; Rodriguez G; Chen SN; Ripplinger CM; Li W; Chen J; Willerson JT; Betocchi S; Wickline SA; Efimov IR; Marian AJ
    Circulation; 2009 Mar; 119(10):1398-407. PubMed ID: 19255346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin activates the PPARγ-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling.
    Zou C; Qi H; Liu ZH; Han L; Zhao C; Yang X
    Tex Heart Inst J; 2013; 40(2):140-7. PubMed ID: 23678211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early diastolic dysfunction of the left ventricle affected by hypertrophy and abnormal histopathology in hypertrophic cardiomyopathy].
    Sugihara N; Shimizu M; Suematsu T; Horita Y; Shimizu K; Ohsato K; Shibayama S; Nakao T; Kitamura M; Takeda R
    J Cardiol; 1990; 20(1):71-81. PubMed ID: 2151236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transgenic rabbit model for human hypertrophic cardiomyopathy.
    Marian AJ; Wu Y; Lim DS; McCluggage M; Youker K; Yu QT; Brugada R; DeMayo F; Quinones M; Roberts R
    J Clin Invest; 1999 Dec; 104(12):1683-92. PubMed ID: 10606622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.
    Takayama N; Kai H; Kudo H; Yasuoka S; Mori T; Anegawa T; Koga M; Kajimoto H; Hirooka Y; Imaizumi T
    Hypertens Res; 2011 Mar; 34(3):341-7. PubMed ID: 21124329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.
    Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF
    Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
    Laufs U; Kilter H; Konkol C; Wassmann S; Böhm M; Nickenig G
    Cardiovasc Res; 2002 Mar; 53(4):911-20. PubMed ID: 11922901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
    Ho CY; López B; Coelho-Filho OR; Lakdawala NK; Cirino AL; Jarolim P; Kwong R; González A; Colan SD; Seidman JG; Díez J; Seidman CE
    N Engl J Med; 2010 Aug; 363(6):552-63. PubMed ID: 20818890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
    Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
    Lim DS; Lutucuta S; Bachireddy P; Youker K; Evans A; Entman M; Roberts R; Marian AJ
    Circulation; 2001 Feb; 103(6):789-91. PubMed ID: 11171784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
    Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible triggers for hypertrophic cardiomyopathy are established in the early postnatal period.
    Cannon L; Yu ZY; Marciniec T; Waardenberg AJ; Iismaa SE; Nikolova-Krstevski V; Neist E; Ohanian M; Qiu MR; Rainer S; Harvey RP; Feneley MP; Graham RM; Fatkin D
    J Am Coll Cardiol; 2015 Feb; 65(6):560-9. PubMed ID: 25677315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YQWY decoction reverses cardiac hypertrophy induced by TAC through inhibiting GATA4 phosphorylation and MAPKs.
    Huang JJ; Xie Y; Li H; Zhang XX; Huang Q; Zhu Y; Gu P; Jiang WM
    Chin J Nat Med; 2019 Oct; 17(10):746-755. PubMed ID: 31703755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac remodeling caused by transgenic overexpression of a corn Rac gene.
    Elnakish MT; Awad MM; Hassona MD; Alhaj MA; Kulkarni A; Citro LA; Sayyid M; Abouelnaga ZA; El-Sayed O; Kuppusamy P; Moldovan L; Khan M; Hassanain HH
    Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H868-80. PubMed ID: 21622832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.
    Penicka M; Gregor P; Kerekes R; Marek D; Curila K; Krupicka J;
    J Mol Diagn; 2009 Jan; 11(1):35-41. PubMed ID: 19074594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.